Clinical Trial Update: Bioequivalence Study of Cephalexin Suspension 250 [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of Cephalexin Suspension 250 mg sponsored by GlaxoSmithKline has completed, assessing formulation equivalence for respiratory tract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Infections

Drugs mentioned

• Cephalexin Suspension 250 mg (cephalexin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Respiratory Tract | Phase 1 | Status: COMPLETED